Breast and ovarian cancer research from 2010 ASCO conference

The most interesting and notable breast and ovarian cancer research from the 2010 ASCO (American Society of Clinical Oncology) conference.

Held in Chicago June 4-8, the annual meeting brought together 50,000 physicians, researchers, and other health care professionals from around the globe to discuss and hear the latest results in cancer research. Click the links to read the articles on the ASCO website.

Treatment Dose, Duration May Predict Response for Various Breast Cancer Subtypes

For patients receiving neoadjuvant therapy for breast cancer, both treatment dose and duration affect the likelihood of attaining a pathologic complete response (pCR), according to results of a pooled multi-layer retrospective analysis presented by Gunter Von Minckwitz, MD, PhD, of Universitäts-Frauenklinik Frankfurt, Germany, and the German Breast Group, during Sunday’s Clinical Science Symposium: “Predictors of Response to Preoperative Therapy: Where Are We?”

Sentinel Node Biopsy Studies Provide Practice-changing Results for Breast Cancer

New data indicate that axillary lymph node dissection is not necessary for women with clinically node-negative breast cancer who undergo sentinel node biopsy. In addition, immunohistochemistry (IHC) provides no additional benefit for patients with clinically node-negative disease and histologically negative nodes.

Serous Ovarian Cancer, But Not Triple-negative Breast Cancer, Responds to Monotherapy with the PARP Inhibitor Olaparib

A phase II translational study of olaparib, an orally active poly (ADP-ribose) polymerase (PARP) inhibitor, showed promising results for women with high-grade serous ovarian cancer regardless of BRCA mutation status

Stay in the Know

Subscribe to the Navigating Cancer blog for the latest news, innovations, and best practices in oncology care.